High Risk Acute Lymphoblastic Leukemia
Conditions
Brief summary
The overall objective of this pilot study is to determine the safety and feasibility of a hybrid closed-loop insulin delivery system for children and young adults with high risk acute lymphoblastic leukemia, during the induction chemotherapy phase while they are exposed to steroids and asparaginase that cause hyperglycemia.
Detailed description
The overall objective of this pilot study is to determine the safety and feasibility of a hybrid closed-loop insulin delivery system for children and young adults with high risk acute lymphoblastic leukemia, during the induction chemotherapy phase while they are exposed to steroids and asparaginase that cause hyperglycemia. Insulin therapy would be beneficial in reducing hyperglycemia-associated complications in this period and thereby could improve other outcomes. The primary objective of the current pilot proposal is to demonstrate that hybrid closed loop pump therapy is a safe to be used in children and young adults with high risk acute lymphoblastic leukemia. If successful, the results of this study will be used to plan and support a larger, multi-center clinical trial and a grant proposal.
Interventions
Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
Sponsors
Children's Hospital Colorado
DexCom, Inc.
Tandem Diabetes Care, Inc.
National Cancer Institute (NCI)
University of Colorado, Denver
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a non-randomized prospective cohort study about the safety and feasibility of a commercially available hybrid closed loop insulin delivery system in children and young adults with high-risk ALL who are at high risk of hyperglycemia due to an intensive chemotherapy regimen containing steroids and asparaginase
Eligibility
Sex/Gender
ALL
Age
10 Years to 26 Years
Healthy volunteers
No
Inclusion criteria
1. Patients ages 10 years old and above 2. Patients who are newly diagnosed with high-risk acute lymphoblastic leukemia 3. Patients who have started or will start an induction chemotherapy regimen containing steroid and asparaginase 4. Patients (if over 18 years of age) or parent/guardian (if the patient is under 18 years of age) must be fluent in reading and speaking English 5. Parent or guardian living in the home with the participant who also receives training on diabetes, CGM, HCL therapy, and the safety protocols
Exclusion criteria
1. Preexisting diabetes 2. Severe psychiatric disease or developmental delays, that might interfere with ability to provide informed consent 3. Active skin condition that would affect sensor placement 4. Any other medical condition which in the opinion of the investigators impairs the person's ability to safely participate in the trial, including but limited to: 1. Significant chronic kidney disease (eGFR \<60) or requiring hemodialysis 2. Significant liver disease 3. History of adrenal insufficiency 4. History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated 5. History of thyroid cancer 5. Use of intravenous or oral acetaminophen more than 60 mg/kg/day (maximum 4000 mg/day)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of infection at the CGM insertion site | 35 days | Rate of infection at the CGM insertion site, measured in occurrences per patient-day. |
| Rate of bleeding at the CGM insertion site | 35 days | Rate of bleeding at the CGM insertion site, measured in occurrence per patient-day. |
| CGM Time in hypoglycemia (blood glucose < 70 mg/dL) | 35 days | The primary outcome measures for this study will be the safety of HCL insulin delivery by hypoglycemia exposure. One of the primary endpoints is CGM Time in hypoglycemia (defined as blood glucose \< 70 mg/dL). |
| Number of episodes of symptomatic hypoglycemia | 35 days | The primary outcome measures for this study will be the safety of HCL insulin delivery by hypoglycemia exposure. One of the primary endpoints is the number of episodes of symptomatic hypoglycemia. At each study visit, subjects will be asked about symptoms, such as shakiness, dizziness, blurred/impaired vision, sweating, pallor, clumsiness, difficulty paying attention, tingling around the lips, tongue or cheeks, change in mental status, or seizure. |
| Rate of infection at the HCL insulin infusion site | 35 days | Rate of infection at the HCL insulin infusion site, measured in occurrence per patient-day. |
| Rate of bleeding at the HCL insulin infusion site | 35 days | Rate of bleeding at the HCL insulin infusion site, measured in occurrence per patient-day. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of glycemic control with HCL insulin delivery assessed by Time in Ranges (TIR) | 35 days | Time in Ranges (TIRs) refers to percent of the time spent in a specific range of blood glucose levels, adding valuable information to assess the level of glycemic control. Usually a range of 70-180 mg/dL is used, but occasionally a more stringent 70-140 mg/dL is used. In this study, we will obtain %CGM TIRs in both ranges. |
| Need for readmission during the induction phase in percent | 35 days | Rate of infection, length of hospitalization, length of PICU admission, rate of remission at the end of induction, and need for re-admission will be obtained as a part of clinical outcomes. These outcomes will be compared to a historical control group to investigate the effect size of relationships between glycemic control and clinical outcome. This exploratory aim will investigate correlations between glycemic control and outcomes to determine effect sizes for future studies and grant proposals. |
| Efficacy of glycemic control with HCL insulin delivery assessed by mean sensor glucose level | 35 days | Mean glucose level will be obtained from CGM data to evaluate for glycemic variability |
| Rate of infection in episodes per patient-days | 35 days | Rate of infection, length of hospitalization, length of PICU admission, rate of remission at the end of induction, and need for re-admission will be obtained as a part of clinical outcomes. These outcomes will be compared to a historical control group to investigate the effect size of relationships between glycemic control and clinical outcome. This exploratory aim will investigate correlations between glycemic control and outcomes to determine effect sizes for future studies and grant proposals. |
| Length of hospitalization in days per patient | 35 days | Rate of infection, length of hospitalization, length of PICU admission, rate of remission at the end of induction, and need for re-admission will be obtained as a part of clinical outcomes. These outcomes will be compared to a historical control group to investigate the effect size of relationships between glycemic control and clinical outcome. This exploratory aim will investigate correlations between glycemic control and outcomes to determine effect sizes for future studies and grant proposals. |
| Length of PICU admission in days per patient | 35 days | Rate of infection, length of hospitalization, length of PICU admission, rate of remission at the end of induction, and need for re-admission will be obtained as a part of clinical outcomes. These outcomes will be compared to a historical control group to investigate the effect size of relationships between glycemic control and clinical outcome. This exploratory aim will investigate correlations between glycemic control and outcomes to determine effect sizes for future studies and grant proposals. |
| Rate of remission at the end of induction in percent | 35 days | Rate of infection, length of hospitalization, length of PICU admission, rate of remission at the end of induction, and need for re-admission will be obtained as a part of clinical outcomes. These outcomes will be compared to a historical control group to investigate the effect size of relationships between glycemic control and clinical outcome. This exploratory aim will investigate correlations between glycemic control and outcomes to determine effect sizes for future studies and grant proposals. |
Countries
United States
Outcome results
None listed